Amedisys, Inc. (NASDAQ:AMED – Get Free Report) has been assigned an average recommendation of “Hold” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $100.75.
Separately, Stephens reissued an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a research note on Wednesday, February 12th.
Check Out Our Latest Report on AMED
Institutional Inflows and Outflows
Amedisys Stock Down 0.1 %
Amedisys stock opened at $92.55 on Wednesday. The firm has a market cap of $3.03 billion, a price-to-earnings ratio of 36.73, a PEG ratio of 1.82 and a beta of 0.73. Amedisys has a 52-week low of $82.15 and a 52-week high of $98.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The firm has a 50 day moving average price of $90.39 and a two-hundred day moving average price of $93.50.
About Amedisys
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Stories
- Five stocks we like better than Amedisys
- How to Most Effectively Use the MarketBeat Earnings Screener
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- How to Use the MarketBeat Excel Dividend Calculator
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.